SC: ऑटिज्म के लिए स्टेम सेल थेरेपी क्लिनिकल सेवा नहीं

The Supreme Court's ruling is in the news because it prohibits unproven stem cell therapies for Autism Spectrum Disorder (ASD) outside of approved clinical trials. This aims to protect vulnerable families from exploitation and ensure ethical medical practices.

For UPSC Prelims, remember these key facts: The Supreme Court has ruled that stem cell therapies cannot be offered as a clinical service for Autism Spectrum Disorder (ASD) outside of approved and monitored clinical trials. The government is directed to establish a dedicated authority for regulatory oversight of stem cell research nationwide. The court also highlighted the lack of established scientific evidence on the efficacy and safety of stem cell therapies for ASD.

Stem cell therapy involves using stem cells to treat or prevent a disease or condition. Regulation is crucial because unproven therapies, like those marketed for ASD, can be ineffective, harmful, and financially exploitative. Without proper oversight, vulnerable individuals and families may be misled and subjected to potentially dangerous treatments.

The ruling protects families with children diagnosed with ASD from being exploited by unproven and potentially harmful stem cell therapies. It emphasizes the need for evidence-based treatments and ethical medical practices, ensuring that families are not misled by false promises of a 'miraculous cure'.

This directive signifies a move towards stricter regulation and monitoring of stem cell research in India. It aims to ensure that all stem cell therapies are evidence-based, safe, and ethically conducted. This authority will likely be responsible for setting standards, approving clinical trials, and taking action against those offering unproven therapies.

The New Drugs and Clinical Trial Rules, 2019, are a set of regulations governing the approval and conduct of clinical trials for new drugs in India. They are relevant because the Supreme Court noted violations of these rules in the marketing and administration of unproven stem cell therapies for autism. The court emphasized that these rules must be strictly followed to ensure patient safety and ethical research practices.

The concept of stem cell therapy began with bone marrow transplantation in the mid-20th century. Research expanded to explore stem cells in regenerative medicine. Recent developments include induced pluripotent stem cells (iPSCs), which allow creating stem cells from adult cells. Clinical trials are ongoing for various conditions.

Ethical considerations include ensuring informed consent, avoiding exploitation, and prioritizing patient safety. In the context of autism, where there is a strong desire for a 'cure,' it's crucial to protect families from unproven and potentially harmful treatments. The Supreme Court emphasized that consent is invalid without proper disclosure of the nature, procedure, benefits, and risks.

Reforms should focus on establishing a robust regulatory authority, enforcing the New Drugs and Clinical Trial Rules, 2019, and promoting evidence-based practices. Increased public awareness about the risks and benefits of stem cell therapies is also crucial. The government needs to actively combat the marketing of unproven therapies and ensure that patients receive accurate and unbiased information.

Justices J.B. Pardiwala and Justice Mahadevan are the key personalities mentioned. They are the judges who delivered the Supreme Court's ruling on stem cell therapy for autism, highlighting the judiciary's role in safeguarding ethical medical practices and protecting vulnerable populations.